Dew, Where did you find that PR? Your sleuthing is amazing. I didn't even find it on the Merrimack website. That's interesting and confirms the rumor that the results from the 2A study were positive. I was thinking that Merrimack was studying AFP in myasthenia gravis. So I was obviously wrong and the potential market for GTCB's recombinant AFP is much bigger than I thought (though I think we know nothing about the deal between GTCB and Merrimack). This adds a little more to GTCB's chances of success, in my estimation.
Market Data 
Markets 
AI
